Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial
Nicholas J. Vogelzang, Tomasz M. Beer, Winald Gerritsen, Stéphane Oudard, Pawel Wiechno, Bozena Kukielka-Budny, Vladimir Samal, Jaroslav Hajek, Susan Feyerabend, Vincent Khoo, Arnulf Stenzl, Tibor Csöszi, Zoran Filipovic, Frederico Goncalves, Alexander Prokhorov, Eric Cheung, Arif Hussain, Nuno Sousa, Amit Bahl, Syed HussainHarald Fricke, Pavla Kadlecova, Tomas Scheiner, Roman P. Korolkiewicz, Jirina Bartunkova, Radek Spisek
Dive into the research topics of 'Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial'. Together they form a unique fingerprint.